Verastem Inc. commenced a public offering of its common stock worth $35 million.

The Needham, Mass.-based biopharmaceutical company granted the underwriter an option to buy up to an additional $5.25 million worth of common shares.

Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering.